…and some to hold, avoid or sell

Indivior Investors Chronicle

The opioid-addiction specialist faces the launch of a cheaper copy of its drug Suboxone and stagnant sales of its new drug Sublocade. Serious legal challenges are becoming “part and parcel”, restricting recovery. Sell. 307.7p.

Mccoll’s Retail Investors Chronicle

The convenience chain has been hit by the collapse of wholesaler Palmer & Harvey. Ongoing cost-cutting combined with rising costs will keep margins under pressure. The departure of the CFO doesn’t help. Sell. 184p.

PZ Cussons Investors Chronicle

Despite tough trading in Nigeria, the consumer goods firm is optimistic and aims to be as “lean and efficient as possible”. Still, commodity costs and exchange rates remain volatile. Sell. 213.6p.

Relx The Times

Relx publishes data and analytics for scientific, legal and financial markets, and operates an exhibition arm. Shares are likely to be unpredictable while it rejigs its dual Anglo-dutch listing and joins the FTSE 100. Avoid. £17.13.

The Daily Telegraph

The builder’s merchant is heavily reliant on the housing market, consumer spending and the weather. It has axed a third of head-office jobs and needs to cut costs further. It may be “some time” before shares recover. Avoid. £13.38.

WPP The Times

Although in recovery mode, the advertising group is still “not in a good place”. Berenberg fears it could lose “a string of accounts” because of the uncertainty, and as it adjusts to changes in the industry. Sell. £11.91.